Hepatic Encephalopathy: a Critical Current Review

Overview

Journal Hepatol Int

Publisher Springer

Specialty Gastroenterology

Date 2017 Aug 4

PMID 28770516

Citations 69

Authors

Anna Hadjihambi

Natalia Arias

Mohammed Sheikh

Rajiv Jalan

Affiliations

Soon will be listed here.

Abstract

Hepatic encephalopathy (HE) is a serious neuropsychiatric complication of cirrhosis and/or porto-systemic shunting. The clinical symptoms are widely variable, extending from subtle impairment in mental state to coma. The utility of categorizing the severity of HE accurately and efficiently serves not only to provide practical functional information about the current clinical status of the patient but also gives valuable prognostic information. In the past 20-30 years, there has been rapid progress in understanding the pathophysiological basis of HE; however, the lack of direct correlation between pathogenic factors and the severity of HE make it difficult to select appropriate therapy for HE patients. In this review, we will discuss the classification system and its limitations, the neuropsychometric assessments and their challenges, as well as the present knowledge on the pathophysiological mechanisms. Despite the many prevalent hypotheses around the pathogenesis of the disease, most treatments focus on targeting and lowering the accumulation of ammonia as well as inflammation. However, treatment of minimal HE remains a huge unmet need and a big concerted effort is needed to better define this condition to allow the development of new therapies. We review the currently available therapies and future approaches to treat HE as well as the scientific and clinical data that support their effectiveness.

Citing Articles

Gray matter alterations and neurotransmitter system associations in hepatitis B virus-related cirrhosis: insights into neuropathogenesis and therapeutic targets.

Gou L, Lei J, Ren H, Zhang Y, Chen X, Wang S Neuroradiology. 2025; .

PMID: 40085214 DOI: 10.1007/s00234-025-03579-0.

Machine learning prediction of hepatic encephalopathy for long-term survival after transjugular intrahepatic portosystemic shunt in acute variceal bleeding.

Liu D, Jia L, Zeng F, Zeng W, Qin G, Peng Q World J Gastroenterol. 2025; 31(4):100401.

PMID: 39877716 PMC: 11718638. DOI: 10.3748/wjg.v31.i4.100401.

Iron overload regulates cognitive function in rats with minimal hepatic encephalopathy by inducing an increase in frontal butyrylcholinesterase activity.

Lan H, Yang X, Wang M, Wang M, Huang X, Wang X Front Aging Neurosci. 2024; 16:1447965.

PMID: 39399316 PMC: 11466795. DOI: 10.3389/fnagi.2024.1447965.

Effect of an Autotaxin Inhibitor, 2-(4-Chlorophenyl)-7-methyl-8-pentylimidazo[1,2-] Pyrimidin-5(8)-one (CBT-295), on Bile Duct Ligation-Induced Chronic Liver Disease and Associated Hepatic Encephalopathy in Rats.

Roy S, Chakrabarti M, Mondal T, Das T, Sarkar T, Datta S ACS Pharmacol Transl Sci. 2024; 7(9):2662-2676.

PMID: 39296254 PMC: 11406694. DOI: 10.1021/acsptsci.4c00066.

Assessment of gnostic and stereognostic functions in patients with liver cirrhosis: A comparative study with healthy controls.

Tapajcikova T, Liska D, Dackeviciene A, Skladany L J Back Musculoskelet Rehabil. 2024; 37(6):1685-1694.

PMID: 39177586 PMC: 11612960. DOI: 10.3233/BMR-240114.

References

Cordoba J, Ventura-Cots M, Simon-Talero M, Amoros A, Pavesi M, Vilstrup H . Characteristics, risk factors, and mortality of cirrhotic patients hospitalized for hepatic encephalopathy with and without acute-on-chronic liver failure (ACLF). J Hepatol. 2013; 60(2):275-81. DOI: 10.1016/j.jhep.2013.10.004. View

Goulenok C, Bernard B, Cadranel J, Thabut D, Di Martino V, Opolon P . Flumazenil vs. placebo in hepatic encephalopathy in patients with cirrhosis: a meta-analysis. Aliment Pharmacol Ther. 2002; 16(3):361-72. DOI: 10.1046/j.1365-2036.2002.01191.x. View

Banares R, Nevens F, Larsen F, Jalan R, Albillos A, Dollinger M . Extracorporeal albumin dialysis with the molecular adsorbent recirculating system in acute-on-chronic liver failure: the RELIEF trial. Hepatology. 2012; 57(3):1153-62. DOI: 10.1002/hep.26185. View

Als-Nielsen B, Gluud L, Gluud C . Benzodiazepine receptor antagonists for hepatic encephalopathy. Cochrane Database Syst Rev. 2004; (2):CD002798. DOI: 10.1002/14651858.CD002798.pub2. View

Hadjihambi A, De Chiara F, Hosford P, Habtetion A, Karagiannis A, Davies N . Ammonia mediates cortical hemichannel dysfunction in rodent models of chronic liver disease. Hepatology. 2017; 65(4):1306-1318. PMC: 5396295. DOI: 10.1002/hep.29031. View

Romero-Gomez M, Boza F, Garcia-Valdecasas M, Garcia E, Aguilar-Reina J . Subclinical hepatic encephalopathy predicts the development of overt hepatic encephalopathy. Am J Gastroenterol. 2001; 96(9):2718-23. DOI: 10.1111/j.1572-0241.2001.04130.x. View

Hassanein T, Hilsabeck R, Perry W . Introduction to the Hepatic Encephalopathy Scoring Algorithm (HESA). Dig Dis Sci. 2007; 53(2):529-38. DOI: 10.1007/s10620-007-9895-0. View

Gluud L, Vilstrup H, Morgan M . Nonabsorbable disaccharides for hepatic encephalopathy: A systematic review and meta-analysis. Hepatology. 2016; 64(3):908-22. DOI: 10.1002/hep.28598. View

Agrawal S, Umapathy S, Dhiman R . Minimal hepatic encephalopathy impairs quality of life. J Clin Exp Hepatol. 2015; 5(Suppl 1):S42-8. PMC: 4442849. DOI: 10.1016/j.jceh.2014.11.006. View

10.

Strauss E, Tramote R, Silva E, Caly W, Honain N, Maffei R . Double-blind randomized clinical trial comparing neomycin and placebo in the treatment of exogenous hepatic encephalopathy. Hepatogastroenterology. 1992; 39(6):542-5. View

11.

Benyoub K, Muller M, Bonnet A, Simon R, Gazon M, Duperret S . Amounts of bile acids and bilirubin removed during single-pass albumin dialysis in patients with liver failure. Ther Apher Dial. 2011; 15(5):504-6. DOI: 10.1111/j.1744-9987.2011.00980.x. View

12.

McGee R, Bakens A, Wiley K, Riordan S, Webster A . Probiotics for patients with hepatic encephalopathy. Cochrane Database Syst Rev. 2011; (11):CD008716. DOI: 10.1002/14651858.CD008716.pub2. View

13.

Hassanein T, Blei A, Perry W, Hilsabeck R, Stange J, Larsen F . Performance of the hepatic encephalopathy scoring algorithm in a clinical trial of patients with cirrhosis and severe hepatic encephalopathy. Am J Gastroenterol. 2009; 104(6):1392-400. DOI: 10.1038/ajg.2009.160. View

14.

Jalan R, Olde Damink S, Hayes P, Deutz N, Lee A . Pathogenesis of intracranial hypertension in acute liver failure: inflammation, ammonia and cerebral blood flow. J Hepatol. 2004; 41(4):613-20. DOI: 10.1016/j.jhep.2004.06.011. View

15.

Shawcross D, Shabbir S, Taylor N, Hughes R . Ammonia and the neutrophil in the pathogenesis of hepatic encephalopathy in cirrhosis. Hepatology. 2009; 51(3):1062-9. DOI: 10.1002/hep.23367. View

16.

Therrien G, Rose C, Butterworth J, Butterworth R . Protective effect of L-carnitine in ammonia-precipitated encephalopathy in the portacaval shunted rat. Hepatology. 1997; 25(3):551-6. DOI: 10.1002/hep.510250310. View

17.

Bajaj J, Sanyal A, Bell D, Gilles H, Heuman D . Predictors of the recurrence of hepatic encephalopathy in lactulose-treated patients. Aliment Pharmacol Ther. 2010; 31(9):1012-7. DOI: 10.1111/j.1365-2036.2010.04257.x. View

18.

Dam G, Keiding S, Munk O, Ott P, Buhl M, Vilstrup H . Branched-chain amino acids increase arterial blood ammonia in spite of enhanced intrinsic muscle ammonia metabolism in patients with cirrhosis and healthy subjects. Am J Physiol Gastrointest Liver Physiol. 2011; 301(2):G269-77. DOI: 10.1152/ajpgi.00062.2011. View

19.

Glass C, Saijo K, Winner B, Marchetto M, Gage F . Mechanisms underlying inflammation in neurodegeneration. Cell. 2010; 140(6):918-34. PMC: 2873093. DOI: 10.1016/j.cell.2010.02.016. View

20.

Wu D, Wu S, Lu J, Zhou Y, Xu L, Guo C . Rifaximin versus Nonabsorbable Disaccharides for the Treatment of Hepatic Encephalopathy: A Meta-Analysis. Gastroenterol Res Pract. 2013; 2013:236963. PMC: 3638683. DOI: 10.1155/2013/236963. View